Mesoblast Limited
ASXMSB heads into its full-year results today with short sellers retreating at the margin — yet the positioning backdrop remains decisively bearish. Short interest has fallen steadily over the past month, dropping roughly 7% to 7.5% of the free float. That is still a meaningful short position for an ASX-listed biotech. Days to cover sit near 29, implying shorts cannot exit quickly…
Snapshot as of 19 Sept 2026
MSB heads into its full-year results today with short sellers retreating at the margin — yet the positioning backdrop remains decisively bearish. Short interest has fallen steadily over the past month, dropping roughly…
MSB has delivered one of its stronger weekly performances in recent memory, gaining 17% to AUD 2.38, while short sellers have quietly trimmed exposure — a combination that makes the lending market the most interesting…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MSB — free to start on ORTEX.
Sign up for free →Open MSB on ORTEX